Advair

Primary Uses

Advair is prescribed for the long-term management of respiratory conditions that cause narrowing of the airways. It contains two active ingredients that work together to reduce inflammation and keep the air passages open over time.

Asthma

This medication is used as a maintenance treatment for asthma in adults and children. It is typically prescribed when asthma symptoms are not sufficiently controlled by a long-term asthma control medicine, such as an inhaled corticosteroid, or when the severity of the condition requires two maintenance therapies.

Chronic Obstructive Pulmonary Disease (COPD)

Advair is used for the long-term treatment of airflow obstruction in patients with COPD, a group of lung diseases that includes:

• Chronic bronchitis
• Emphysema

In patients with COPD, it is also used to help reduce the frequency of flare-ups or worsening of symptoms.

Important Limitations

Advair is a maintenance medication and must be used regularly to be effective. It is not a rescue inhaler and will not work fast enough to treat a sudden asthma attack or an acute episode of shortness of breath. A separate fast-acting rescue inhaler is required for emergency symptom relief.

Mechanism of Action

Advair contains two active ingredients that target different aspects of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD):

• Fluticasone: This is a corticosteroid that helps reduce and prevent inflammation. It works by decreasing swelling and irritation in the walls of the small air passages in the lungs, making them less sensitive to triggers.
• Salmeterol: This is a long-acting bronchodilator. It works by relaxing the smooth muscles that surround the airways. When these muscles are relaxed, the airways stay open wider, allowing air to flow in and out more easily.

By using these two medications together, Advair helps to manage both the underlying inflammation and the physical narrowing of the airways. This combination is designed for long-term maintenance and is intended to prevent symptoms such as wheezing, shortness of breath, and coughing. It does not work immediately and should not be used as a rescue inhaler for sudden breathing problems.

Common Side Effects

Many people using this medication experience mild symptoms. Common side effects include:

• Headache and dizziness
• Nausea, vomiting, or stomach upset
• Throat irritation, hoarseness, or voice changes
• Cough, runny nose, or sinus pain
• Muscle, bone, or back pain
• White patches in the mouth or on the tongue (oral thrush)

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider if you experience:

• Breathing problems: Sudden, severe wheezing or difficulty breathing immediately after using the inhaler.
• Heart issues: Chest pain or a fast, pounding, or irregular heartbeat.
• Nervous system symptoms: Tremors, nervousness, or feeling shaky.
• Vision changes: Blurred vision, eye pain, or seeing halos around lights.
• Signs of infection: Fever, chills, or a persistent sore throat. Patients with COPD may have an increased risk of pneumonia.
• Hormonal or metabolic changes: Increased thirst, frequent urination, extreme tiredness, or muscle weakness.
• Allergic reactions: Severe rash, hives, or swelling of the face, lips, or tongue.

Long-term use of inhaled corticosteroids may also lead to decreased bone mineral density or slowed growth in children and adolescents.

Not for Acute Symptoms

Advair is intended for the long-term maintenance of asthma and COPD. It is not a rescue medication and will not work fast enough to treat a sudden asthma attack or acute bronchospasm. A separate rescue inhaler, such as albuterol, must be used for sudden symptoms.

Asthma-Related Risks

The salmeterol component in Advair is a long-acting beta-agonist (LABA). While LABAs used alone can increase the risk of asthma-related hospitalization and death, Advair combines a LABA with an inhaled corticosteroid to reduce these risks. It should only be used in patients whose asthma is not well-controlled on a long-term asthma-control medication alone.

Infection and Immune System Risks

Advair can increase the risk of developing fungal infections (thrush) in the mouth and throat. To reduce this risk, users should rinse their mouth with water without swallowing after each dose. Additionally, the steroid component may weaken the immune system, making it harder to fight infections. Individuals should avoid exposure to chickenpox or measles while using this medication.

Long-Term Steroid Effects

Prolonged use of inhaled corticosteroids like fluticasone may lead to several systemic health concerns:

• Bone Health: Long-term use may lead to a decrease in bone mineral density, which can increase the risk of osteoporosis.
• Eye Problems: There is an increased risk of developing glaucoma or cataracts.
• Growth in Children: Inhaled steroids may cause a slowing of the growth rate in children and adolescents.

Cardiovascular and Metabolic Concerns

Advair should be used with caution in individuals with certain medical conditions:

• Heart Conditions: The medication can cause cardiovascular effects, including increased pulse rate, elevated blood pressure, or abnormal heart rhythms.
• Diabetes: It may cause an increase in blood sugar levels (hyperglycemia).
• Thyroid and Seizures: Caution is advised for those with hyperthyroidism or seizure disorders.

Pneumonia Risk in COPD

Patients using Advair for the treatment of chronic obstructive pulmonary disease (COPD) have an increased risk of developing pneumonia. Medical attention should be sought if symptoms of a lung infection, such as fever, chills, or increased mucus production, occur.

Pregnancy

There is limited information regarding the safety of using Advair during pregnancy. While some animal studies have suggested potential risks to a developing fetus, there are no adequate and well-controlled studies in humans. However, it is important to note that poorly controlled asthma during pregnancy can lead to complications for both the mother and the baby, such as preeclampsia or low birth weight.

If you are pregnant or planning to become pregnant, discuss the risks and benefits of continuing this medication with your healthcare provider. They will help determine if the treatment is necessary for managing your respiratory condition during this time.

Breastfeeding

It is currently unknown whether the active ingredients in Advair, fluticasone and salmeterol, pass into human breast milk. There is also limited information on how the drug might affect a breastfeeding child or the mother's milk production. Because many drugs are excreted in human milk, caution is advised. Consult with a healthcare professional to weigh the benefits of breastfeeding against the potential risks to the infant while using this medication.

Dosage Forms

Advair is provided in the following forms for oral inhalation:

• Advair Diskus: This is a dry powder inhaler. It contains a foil strip with individual blisters of medication that are opened and inhaled through the device.
• Advair HFA: This is an inhalation aerosol. It uses a pressurized canister to deliver the medication as a spray.

Strengths

Both the powder and aerosol forms are available in multiple strengths. Each dose contains a combination of fluticasone propionate and salmeterol. The specific strength prescribed depends on whether the medication is being used for asthma or chronic obstructive pulmonary disease (COPD), as well as the patient's age and the severity of their symptoms.

FDA Approval and Indications

Advair Diskus and Advair HFA are approved by the U.S. Food and Drug Administration (FDA) for the long-term treatment of asthma. Advair Diskus is also specifically approved for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Age Requirements

• Advair Diskus: Approved for asthma in patients 4 years of age and older.
• Advair HFA: Approved for asthma in patients 12 years of age and older.
• COPD: Advair Diskus is approved for use in adults with COPD; it is not indicated for COPD in children.

Regulatory History and Safety

The FDA previously required a Boxed Warning for all medications containing long-acting beta2-adrenergic agonists (LABAs) because of a perceived risk of asthma-related death. After reviewing results from several large safety trials, the FDA determined that the risk of serious asthma-related outcomes is not significantly increased when a LABA is used in combination with an inhaled corticosteroid (ICS). Consequently, the Boxed Warning was removed from the labeling for Advair and similar combination products.

Generic Availability

The FDA has approved generic versions of fluticasone and salmeterol inhalation powder, providing additional regulated options for patients requiring this combination therapy.

Generic Availability

Generic versions of fluticasone and salmeterol are available for the Advair Diskus formulation. Generic medications typically cost significantly less than brand-name versions while containing the same active ingredients. Generic availability for the Advair HFA formulation may be more limited.

Factors Influencing Price

Several factors can affect the out-of-pocket cost for this medication:

• Insurance Coverage: Health insurance plans vary in how they cover Advair. Some plans may place the brand-name version in a higher cost-sharing tier or require the use of a generic alternative first.
• Pharmacy Choice: Prices can vary between different retail pharmacies, and mail-order pharmacy services may offer different pricing structures.
• Formulation: The price may differ between the dry powder inhaler (Diskus) and the metered-dose aerosol inhaler (HFA).

Financial Assistance

Patients without insurance or those with high out-of-pocket costs may be eligible for manufacturer patient assistance programs or savings cards. Some pharmacies also offer discount programs that can reduce the retail price of both brand-name and generic versions.